Keep up to date with our latest partnering deals and highlights
Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.
- Thursday, 10 July 2014
- New drug active against most aggressive type of lung cancer cells Manchester scientists have shown that a new drug could prove useful in treating small cell lung cancer - the most aggressive form of lung cancer.
- Thursday, 3 July 2014
- MRC Technology and AstraZeneca Renew Collaboration to Identify Novel Targets for Discovery Research Initiative brings together global expertise to share compound libraries and streamline drug discovery
- Thursday, 12 June 2014
- AstraZeneca in-licenses Synairgen’s SNG001 as a novel immuno-modulatory therapy for viral-induced exacerbation in asthma Phase IIa clinical study to commence in patients with severe asthma